Table 10. Baseline characteristics of observational studies evaluating venous thromboembolism prophylaxis in major orthopedic surgery.

| Study, Year | Group | N | Age  mean (SD) | Female  % | Wt kg mean (SD) | Smoker  % | Obese  % | Hx VTE  % | Varic-osity % | Estr-ogen  % | DM  % | CA % | CVD % | Previous ortho-pedic surgery % |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bozic, 2010 | Warfarin | 51923 | 67.3 (10.4) | 65.17 | --- | 5 | 12 | --- | --- | --- | 17 | 0.6 | --- | --- |
|  | Aspirin | 4719 | 66.4 (10.7) | 64.42 | --- | 6 | 18 | --- | --- | --- | 16 | 0.4 | --- | --- |
| Gerkens, 2010 | Enoxaparin | 6700 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Fondaparinux | 122 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Control | 115 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cusick, 2009 THR | Aspirin | 2094 | 68 (19-93)\* † | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Warfarin | 6 |  | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Control | 86 |  | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cusick, 2009 TKR | Aspirin | 1966 | 71 (31-93)\* † | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Warfarin | 5 |  | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Control | 50 |  | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Froimson, 2009 | IPC (ActiveCare) | 223 | 66 (11.5) | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | IPC  (Flowtron) | 1354 | 64.3 (13.7) | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Gandhi, 2009 | Metabolic syndrome | 135 | 66.1 (9.2) | 67.00 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Without metabolic syndrome | 1325 | 66.6 (9.9) | 63.5 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| McNamara, 2009 | Thrombosis | 117 | 79(12) | 82.91 | --- | 14.02 | --- | --- | --- | --- | --- | --- | --- | --- |
|  | No thrombosis | 5183 | 80 (11) | 78.37 | --- | 12.53 | --- | --- | --- | --- | --- | --- | --- | --- |
| Dorr, 2007 | Low risk | 856 | 64.9 (11.9)† | 56.9† | 83.9 (21.1)† | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | High risk | 114 |  | --- |  | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Shorr, 2007 | Fondaparinux | 12532 | 69 | 63.4 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Enoxaparin | 97827 | 70 | 65.2 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Dalteparin | 16109 | 68 | 63.5 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | UFH | 18338 | 69 | 63.6 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Control | 112574 | 68 | 63.0 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Leirozovicz,2005 | sVTE or death | 28 | 72 (68-80)\* | 67.9 | --- | --- | 18.2 | 3.6 | 14.3 | 0.0/  0.0‡ | --- | 7.1 | --- | --- |
|  | No sVTE or death | 2392 | 68 (60-75)\* | 67.3 | --- | --- | 12.1 | 0.2 | 4.2 | 0.2/  0.5‡ | --- | 3.2 | --- | --- |
| Sachs, 2003 | Warfarin | 957 | 70 | 56† | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Control | 785 | 70 |  | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ryan, 1998 | Factor V Leiden mutation | 32 | 66.0 (12.1) | 47 | --- | --- | --- | 4 | --- | --- | --- | --- | --- | --- |
|  | Without Factor V Leiden mutation | 793 | 66.9 (11.1) | 57 | --- | --- | --- | 8.6 | --- | --- | --- | --- | --- | --- |
| Lieberman, 1997 | Before hospital discharge | 1042† | 59 (19-90)\*† | --- | --- | --- | ---- | 20†§ | --- | --- | --- | --- | --- | --- |
|  | After hospital discharge |  |  | --- | --- | --- | --- |  | --- | --- | --- | --- | --- | --- |
| Haas, 1992 | No thrombi | 498 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Calf thrombi | 655 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Proximal thrombi | 104 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lemos, 1991 | PE | 81 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Without PE | 159 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

\*Mean(range)

†Value for the total study population

‡Estrogen/HRT use

§History of symptomatic pulmonary embolism or deep vein thrombosis

Abbreviations: BMI=body mass index; CA=cancer; CVD=cardiovascular disease; DM=diabetes mellitus; hx=history; IPC=intermittent pneumatic compression; kg=kilograms; LMWH=low molecular weight heparin; PE=pulmonary embolism; SD=standard deviation; sVTE=symptomatic venous thromboembolism; THR=total hip replacement; TKR=total knee replacement; UFH=unfractionated heparin; VTE=venous thromboembolism; Wt=weight